Rhythm’s Imcivree (setmelanotide) Receives Health Canada Approval for Weight Management in Adult and Pediatric Patients with Obesity
Shots:
- Health Canada has approved Imcivree (SC) for weight management in adult & pediatric patients aged ≥6yrs. with obesity due to BBS or genetically confirmed biallelic POMC, PCSK1, or LEPR deficiency due to variants interpreted as pathogenic, likely pathogenic, or of uncertain significance
- The approval was based on the largest studies evaluating Imcivree. The P-III study results from 52 patients showed that 32·3% of patients reached a 10% reduction in body weight after 52wks.
- The trials met all 1EPs & 2EPs i.e., the therapy was well-tolerated & trials were featured in multiple publications, incl. The Lancet Diabetes and Endocrinology. The product is expected to be commercially available in Canada in the months
Ref: Rhythm | Image: Rhythm
Related News:- Rhythm Pharmaceuticals Launches Imcivree (setmelanotide) for Obesity and Control of Hunger in Bardet-Biedl Syndrome in Germany
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
